LSTA
Lisata Therapeutics, Inc.2.0500
+0.0100+0.49%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
18.08MP/E (TTM)
-Basic EPS (TTM)
-2.13Dividend Yield
0%Recent Filings
10-K
8-K
Lisata merger: $5 + CVR
Lisata Therapeutics signed a merger agreement on March 6, 2026, with Kuva Labs for a tender offer of $5.00 cash per common share plus a non-tradable CVR worth $1.00 if certepetide hits an NDA milestone by the seventh anniversary of closing. The board unanimously recommends tendering shares; deal targets Q2 2026 close sans financing condition. CVR payout hinges on regulatory filing.
8-K
Lisata extends acquisition term sheet
8-K
Terminates China certepetide deal
Lisata Therapeutics terminated its exclusive license and collaboration agreement with Qilu Pharmaceutical for certepetide in Greater China, effective January 23, 2026. The deal had offered up to $200 million in milestones and 10-15% royalties. Rights revert fully. Termination spares prior obligations.
8-K
Lisata acquisition term sheet signed
Lisata Therapeutics signed a binding term sheet on January 20, 2026, for acquisition by Kuva Labs via tender offer at $4.00 per share in cash, plus two $1.00 CVRs tied to certepetide milestones in Greater China and NDA filing. Lisata's board unanimously approved, targeting definitive agreement by February 27. Deal includes $2M breakup fees. Risks loom if conditions fail.
CARM
Carisma Therapeutics, Inc.
0.05+0.00
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
DRMA
Dermata Therapeutics, Inc.
2.32-0.16
LIMN
Liminatus Pharma, Inc.
0.78+0.02
LIXT
Lixte Biotechnology Holdings, I
4.10+0.11
LRMR
Larimar Therapeutics, Inc.
3.74-0.18
MRKR
Marker Therapeutics, Inc.
1.27-0.12
RNXT
RenovoRx, Inc.
0.84-0.10
SLNO
Soleno Therapeutics, Inc.
49.50-0.45
SNSE
Sensei Biotherapeutics, Inc.
8.08+0.19